Premium
The Impact of Preclinical Irreproducibility on Drug Development
Author(s) -
Freedman LP,
Gibson MC
Publication year - 2015
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.9
Subject(s) - drug development , reproducibility , preclinical research , computer science , medicine , data collection , medical physics , drug , pharmacology , mathematics , statistics
The development of novel therapeutics depends and builds upon the validity and reproducibility of previously published data and findings. Yet irreproducibility is pervasive in preclinical life science research and can be traced to cumulative errors or flaws in several areas, including reference materials, study design, laboratory protocols, and data collection and analysis. The expanded development and use of consensus‐based standards and well‐documented best practices is needed to both enhance reproducibility and drive therapeutic innovations.